Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome

British Journal of Cancer

Volumn 83, Issue 4, 2000, Pages 447-453

  Anderson, H ^a   Hopwood, P ^b   Stephens, R J ^c   Thatcher, N ^b   Cottier, B ^d   Nicholson, M ^e   Milroy, R ^f   Maughan, T S ^g   Falk, S J ^h   Bond, M G ⁱ   Burt, P A ^b   Connolly, C K ^j   McIllmurray, M B ^k   Carmichael, J ^l  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d CLATTERBRIDGE HOSPITAL   (United Kingdom)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^g VELINDRE CANCER CENTRE   (United Kingdom)

^h BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

ⁱ United Kingdom   (United Kingdom)

^j DARLINGTON MEMORIAL HOSPITAL   (United Kingdom)

^k ROYAL LANCASTER INFIRMARY   (United Kingdom)

^l NOTTINGHAM CITY HOSPITAL   (United Kingdom)

more..

Author keywords

BSC; Gemcitabine; NSCLC; Quality of life

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANKLE EDEMA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; FEMALE; FLU LIKE SYNDROME; HAIR LOSS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0033913982     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1307     Document Type: Article

References (30)

1. Aapro MS, Martin C and Hatty S (1998) Gemeitabine: a safety review. Anti-Cancer Drugs 9: 191-201
2. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleisham SB and deHaes JC (1993) The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
3. Barsevik A, Langer C, Brunet D, Grindel C, Leighton J and Luckscheider C (1997) Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel [abstract]. Proc Am Soc Clin Oncol 16:44a
4. Batel-Copel M, Kornblith AB and Batel PC (1997) Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer 33: 29-32
5. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S and Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A(5): 635-642
6. Bernhard J and Gelber RD (eds) (1998) Workshop on missing data in quality of life research in cancer clinical trials: practical and methodological issues. Stat Med 17: 5-7
7. Billingham LJ, Cullen MH, Woods AD and Chetiyawardana RC (1997) Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer: 3. Results of a randomised trial evaluating palliation and quality of life [abstract]. Lung Cancer 18(Suppl 1): 9
8. Brinkley D (1985) Quality of life in cancer trials. BMJ 291: 685-686
9. Cox JD, Stetz J and Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5): 1341-1346
10. Cullen MH (1993) The MIC regimen in non-small cell lung cancer. Lung Cancer 9(Suppl 2): 81-89
11. Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66-72
12. Fernandez C, Rosell R and Abad Esteve A et al (1989) Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 28: 29-33
13. Hardy JR, Noble T and Smith IE (1989) Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 60: 764-766
14. Harper PG, James LE, Spiro SG and Rudd RM (1997) Five day oral etoposide treatment for advanced small cell lung cancer (SCLC): quality of life (QOL) assessments in a randomised comparison with intravenous chemotherapy [abstract]. Lung Cancer (18 Suppl 1): 204
15. Hopwood P (1996) Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Semin Oncol 23(5 Suppl 10): 60-64
16. Hopwood P (1997) Evidence for the impact of quality of life. Lung Cancer 18(Suppl 2): 66
17. Hopwood P, Stephens RJ and Machin D, for the MRC Lung Cancer Working Party (1994) Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 3: 339-352
18. Hopwood P and Stephens RJ, on behalf of the Medical Research Council (MRC) Lung Cancer Working Party (1995) Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer 7: 633-636
19. Hopwood P, Harvey A, Davies J, Stephens RJ, Girling DJ, Gibson D and Parmar MK (1998) Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. Eur J Cancer 34(1): 49-57
20. MRC LCWP (1996a) Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 73: 406-413
21. MRC LCWP (1996b). Randomised trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol 8: 167-75
22. Noble S and Goa KL (1997) Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54: 447-472
23. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909
24. Pocock S and Simon R (1975) Sequential treatment assignment with balancing of prognostic factors in controlled clinical trials. Biometrics 31: 103-115
25. Stephens RJ, Hopwood P, Girling DJ and Machin D (1997) Randomized trials with quality of life endpoints. Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 6: 225-236
26. Stephens RJ, Hopwood P and Girling D (1999) Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 79: 538-544
27. Stewart LA, Pignon JP, Parmar MKB, Le Chevalier T and Souhami RL, on behalf of the NSCLC Collaborators Group (1994) A meta-analysis using individual patient data from randomised clinical trials (RCTs) of chemotherapy (CT) in non-small cell lung cancer (NSCLC): (3) Survival in the supportive care setting [abstract]. Proc Am Soc Clin Oncol 13: 337
28. Thatcher N, Anderson H, Betticher DC and Ranson M (1995) Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anti-Cancer Drugs 6(Suppl 6): 39-48
29. Thatcher N, Hopwood P and Anderson H (1997) Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancel 33(Suppl 1): S8-S13
30. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization 48: Geneva